Yael Weiss
Founder
Mahzi Therapeutics
Mahzi Therapeutics develops targeted therapies for under-served rare genetic neurodevelopmental disorders by collaborating with patient groups, academic researchers, and industry experts. The company aims to address the lack of effective treatment options for these serious conditions through a unified approach to research and development.
- Biotechnology
Updated 7 months ago
Funding
Raised to date
$56.1MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Problem
Many rare genetic neurodevelopmental disorders lack effective treatment options, leaving a significant unmet need for patients and their families. The limited availability of therapies can result in a diminished quality of life and increased burden on healthcare systems.
Solution
Mahzi Therapeutics is dedicated to developing targeted therapies for under-served rare genetic neurodevelopmental disorders. By fostering collaboration between patient groups, academic researchers, and industry experts, Mahzi aims to accelerate the development of effective treatments. The company employs a unified approach to research and development, leveraging collective expertise to address the unique challenges associated with these conditions. Mahzi's approach seeks to improve the lives of patients and families affected by these disorders.
Target Audience
Mahzi Therapeutics focuses on patients and families affected by rare genetic neurodevelopmental disorders, as well as the healthcare professionals who treat them.
Features
- Collaborative approach uniting patient groups, academic researchers, and industry experts
- Focus on developing targeted therapies for rare genetic neurodevelopmental disorders
- Unified research and development strategy